Board of Directors

ERX Pharmaceuticals benefits from a team of world-renowned scientific, clinical, and business advisors.

Mr. Uysal is a co-founder of ERX Pharmaceuticals and has been President, Chief Executive Officer, and a director of the Company since its inception. With a career spanning two decades, he is an experienced scientist, entrepreneur, executive, and venture capitalist across diverse technology sectors. Prior to ERX, he was the Director of New Ventures and Entrepreneurship at King Abdullah University of Science and Technology in Saudi Arabia where he oversaw three programs providing capital and advisory support to entrepreneurs forming new companies based on innovative technologies – Entrepreneurship Center, Seed Fund, and Early Stage Fund. Prior to that he was also a co-founder and former President and Chief Executive Officer of Syndexa Pharmaceuticals, a Boston-based metabolic diseases therapeutics company. Mr. Uysal has worked in various capacities in the life sciences and pharmaceuticals sectors at PwC/PRTM, Precision Therapeutics, Inc., and Polaris Venture Partners. He started his professional life as a scientist at Harvard University, where he conducted biomedical research in the field of metabolic diseases and co-authored 17 original research articles. He holds an M.B.A. from Carnegie Mellon Tepper School of Business and a B.A. from Brandeis University. He also attended Harvard Medical School and Harvard University where he successfully completed various advanced biomedical courses.

Dr. Ozcan is a physician-scientist and co-founder of ERX Pharmaceuticals. He has been a member of the ERX Board since its inception and serves as the chair of the scientific advisory board. Dr. Ozcan is an associate professor of pediatrics at Boston Children’s Hospital, Harvard Medical School. His research mainly focuses on understanding the molecular mechanisms of leptin resistance in obesity. In 2009, Dr. Ozcan showed that increased endoplasmic reticulum stress in the brain of obese mice led to the development of leptin resistance and obesity. In subsequent studies, Dr. Ozcan reported the identification and use of leptin sensitizers to reduce leptin resistance and consequently treat obesity in animal models, which became the scientific foundation for starting the company. Dr. Ozcan holds an M.D. from the University of Istanbul and completed his research training at the Joslin Diabetes Center and the Harvard School of Public Health.

Dr. Bodnar is an independent pharmaceutical consultant who has been a member of the ERX Board since 2016. He served as Associate Chief of both the Cardiac Unit and the Department of Internal Medicine at Massachusetts General Hospital and was a faculty member at Harvard Medical School before moving to Bristol-Myers Squibb Co. (BMS). During his 17 years at BMS, Dr. Bodnar had senior level responsibility in diverse areas, including R&D, strategic marketing, business development, legal, corporate strategy, and leadership of various businesses. In his current role, Dr. Bodnar provides consulting and advisory services to pharmaceutical companies on scientific, medical, legal, regulatory, strategic, and business matters.

Dr. Friedman has been a member of the ERX Board since 2018. He is a physician scientist studying the molecular mechanisms that regulate body weight. Dr. Friedman’s research on various aspects of obesity received national attention in late 1994, when it was announced that he and his colleagues had isolated the mouse ob gene and its human homologue encoding the leptin hormone. Leptin regulates food intake and body weight in rodents and humans. His current research on leptin is aimed at understanding the neural circuit regulated by leptin. Dr. Friedman is a Professor at the Rockefeller University and an Investigator at the Howard Hughes Medical Institute. Dr. Friedman received his M.D. from Albany Medical College in 1977, where he also completed a medical residency. He received his Ph.D. in 1986 at Rockefeller University. His many awards and honors include the Wolf Prize in Medicine, the Albert Lasker Basic Medical Research Award, the BBVA Foundation Frontiers of Knowledge Award, the Shaw Prize for Life Sciences and Medicine, and the Gairdner Foundation International Award. Dr. Friedman was also a Founder of Millennium Pharmaceuticals and Envoy Therapeutics and has served on numerous Advisory Boards for private and publicly traded companies.

Dr. Zheng has been a member of the ERX Board since 2018. She is the President of GP Capital Emerging Industry Co. Ltd., leading over 10 direct overseas investments across US and Europe, most of which are pharmaceutical companies. Before joining GP Capital, Dr. Zheng worked as a physician for nine years and in investment banking for 15 years. She was the former project manager of the investment banking department of Haitong Securities Co., Ltd., assistant general manager of the Shanghai investment bank department of Taiyang Securities Co., Ltd., managing director and deputy general manager of the investment banking department of Qilu Securities Co., Ltd., and the executive deputy general manager and managing director of the investment banking department of Huafu Securities Co., Ltd. Dr. Zheng has led a series of IPO projects, including Chang Dian Technology (the first packaging testing enterprise in China), Da Gang Joint-stock Company, Xin Peng Industry Ltd. (the first professional sheet metal IPO in China), Bao Tong Belt Industry Ltd., NGS Real Estate, Jiangsu Sfere Electric Co. Ltd., among others. She presided over the audit and investment decision-making of more than 10 projects when she took a dual role in the first investment decision-making committee of Qilu Securities Direct Investment Corporation. She received a Bachelor of Clinical Medicine from Fudan University’s School of Medicine, and an MBA from Shanghai University of Finance and Economics.